IMP Release and Supply Management: Ensuring Compliance from Manufacture to Site – Part 6
For Chinese biotech sponsors expanding clinical trials into Europe, managing investigational medicinal product (IMP) release and supply is a critical operational and regulatory responsibility. From manufacturing through to distribution at the trial site, every step must comply with EU requirements, including Good Manufacturing Practice (GMP), Good Distribution Practice (GDP), and Qualified Person (QP) release obligations. Effective IMP management ensures patient safety, trial integrity, and uninterrupted study timelines.
GMP and QP Release: Ensuring IMP Quality
All investigational products destined for EU clinical trials must be manufactured under GMP conditions. Compliance requires documented quality systems, validated processes, and robust batch records. Before any batch can be released for clinical use, a Qualified Person (QP) must review manufacturing and testing data to confirm compliance with EU GMP and the approved clinical trial documentation. The QP serves as the legal and operational guarantor that the IMP is safe, of appropriate quality, and ready for administration in clinical trial. For multinational studies, QP release is particularly important, as it ensures regulatory alignment across multiple EU Member States and provides inspectors with auditable documentation of compliance.
Importation and EU Site Supply
When IMPs are manufactured outside the EU, importation is subject to strict EU regulations. Sponsors must hold or work with a Responsible Person (RP) authorized for import, and all shipments must comply with import permits, customs requirements, and GDP standards. Documentation must accompany each shipment, including batch certificates, QP release confirmation, and shipping manifests. Ensuring temperature-controlled logistics and monitoring during transport is critical for IMP stability and patient safety.
Once imported, IMPs must be distributed to clinical sites following GDP guidelines, maintaining traceability and accountability. Sponsors must ensure proper labeling, handling, and storage at each site, and train site staff on product administration, handling, and reporting of any deviations. Integrated tracking systems help monitor inventory, expiration dates, and chain-of-custody, reducing the risk of interruptions in dosing or protocol deviations.
Managing Multiregional Complexity
For multinational trials, IMP supply management can be particularly complex. EU Member States may require local language labeling or may have specific import, customs clearance or distribution requirements. Coordinating manufacturing, QP release, customs clearance, and site delivery across multiple countries requires careful planning and strong collaboration between sponsors, CROs, distributors, and clinical sites. Delays in any step can affect dosing schedules, trial timelines, and ultimately patient safety and data integrity.
Operational Best Practices
Sponsors can improve IMP supply chain reliability by integrating several operational practices:
– Early engagement with QP and RP to confirm release and import procedures.
– Maintaining validated temperature-controlled shipping and storage solutions.
– Using centralized or harmonized labeling and documentation to meet multiregional requirements.
– Implementing robust inventory management and monitoring systems at both depots and sites.
– Training site staff on IMP handling, accountability, and reporting of any discrepancies or deviations.
Strategic Advantage Through Compliance
Efficient IMP release and supply management is more than regulatory compliance — it is a critical enabler of smooth trial execution. Sponsors who plan and execute IMP logistics effectively can prevent dosing interruptions, reduce site queries and audit findings, and maintain patient safety. For Chinese biotech companies entering Europe, mastering EU GMP, QP release, and GDP obligations ensures that investigational products are delivered reliably and compliantly to every site, supporting timely data collection and overall trial success.
By embedding regulatory compliance into the IMP supply chain and operational workflow, sponsors can turn a complex process into a strategic advantage — demonstrating capability, reliability, and commitment to patient safety across all trial regions.
Previous blog: Data Protection and Cross-Border Transfers- Caidya®